Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
To experience MinuteCE for yourself, select one of the episodes below to start learning!
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
What Is the Future of Neoadjuvant ARI Intensification in Localized Prostate Cancer?
What Is the Future of Neoadjuvant ARI Intensification in Localized Prostate Cancer?
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for GI Bleeds?
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for GI Bleeds?
Setting the Stage: Case Considerations for Bleeding Management in Anticoagulated Patients
Setting the Stage: Case Considerations for Bleeding Management in Anticoagulated Patients
What Future Studies Are Out There on the Meaningfulness of Reversal in ICH?
What Future Studies Are Out There on the Meaningfulness of Reversal in ICH?
Clinical and Practical Viability of RWE – What Now?
Clinical and Practical Viability of RWE – What Now?
Anticoagulant-Associated Major Bleeding Is a Significant Problem: How Do I Address?
Anticoagulant-Associated Major Bleeding Is a Significant Problem: How Do I Address?
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for ICH?
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for ICH?
What’s the Best Available Evidence for Reversal of Life-Threatening Bleeds?
What’s the Best Available Evidence for Reversal of Life-Threatening Bleeds?
Newest Emerging Data from ISTH: Andexanet Alfa vs. 4F-PCC?
Newest Emerging Data from ISTH: Andexanet Alfa vs. 4F-PCC?
Case: Using the 2022 ESC/ERS Treatment Algorithm in Older Male Patient with Cardiopulmonary Comorbidities
Case: Using the 2022 ESC/ERS Treatment Algorithm in Older Male Patient with Cardiopulmonary Comorbidities